Simcere Pharmaceutical

[Not Yet Scheduled]
Simcere Pharmaceutical Group Limited is rapidly transitioning to an innovation and R&D-driven pharmaceutical company, with a mission of “providing today’s patients with medicines of the future.” It has established the State Key Laboratory of Translational Medicine and Innovative Drug Development. Simcere focuses on three therapeutic areas: oncology, central nervous system diseases and autoimmune diseases, with a diversified product portfolio and industry-leading capabilities. Its vigorous in-house R&D efforts and extensive R&D collaborations have made it a strategic cooperation partner with world leading pharmaceutical companies and biotechnology companies, in an effort to bring more global life science breakthroughs to China. Simcere has been continuously recognized as one of the “Top 10 Innovative Pharmaceutical Enterprises in China” and “Top 100 Pharmaceutical Manufacturing Enterprises of China ”.
Ticker:
2096.HK
Exchange:
Hong Kong
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
1995
Main Therapeutic Focus:
Lead Product in Development:
Sanbexin
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
7
Speaker
photo
SVP, Head of Global BD
Simcere Pharmaceutical